Vereecken P - Search Results

1

High serum galectin-3 in advanced melanoma: preliminary results.

Vereecken P, Zouaoui Boudjeltia K, Debray C, Awada A, Legssyer I, Sales F, Petein M, Vanhaeverbeek M, Ghanem G, Heenen M. Vereecken P, et al. Clin Exp Dermatol. 2006 Jan;31(1):105-9. doi: 10.1111/j.1365-2230.2005.01992.x. Clin Exp Dermatol. 2006. PMID: 16309497

2

Expression of galectin-3 in primary and metastatic melanoma: immunohistochemical studies on human lesions and nude mice xenograft tumors.

Vereecken P, Debray C, Petein M, Awada A, Lalmand MC, Laporte M, Van Den Heule B, Verhest A, Pochet R, Heenen M. Vereecken P, et al. Arch Dermatol Res. 2005 Feb;296(8):353-8. doi: 10.1007/s00403-004-0536-6. Epub 2005 Jan 11. Arch Dermatol Res. 2005. PMID: 15645276

3

Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients.

Vereecken P, Awada A, Suciu S, Castro G, Morandini R, Litynska A, Lienard D, Ezzedine K, Ghanem G, Heenen M. Vereecken P, et al. Melanoma Res. 2009 Oct;19(5):316-20. doi: 10.1097/CMR.0b013e32832ec001. Melanoma Res. 2009. PMID: 19581819

4

Evaluation of extensive initial staging procedure in intermediate/high-risk melanoma patients.

Vereecken P, Laporte M, Petein M, Steels E, Heenen M. Vereecken P, et al. J Eur Acad Dermatol Venereol. 2005 Jan;19(1):66-73. doi: 10.1111/j.1468-3083.2004.01130.x. J Eur Acad Dermatol Venereol. 2005. PMID: 15649194

5

Interferon alpha as adjuvant postsurgical treatment of melanoma: a meta-analysis.

Pirard D, Heenen M, Melot C, Vereecken P. Pirard D, et al. Among authors: vereecken p. Dermatology. 2004;208(1):43-8. doi: 10.1159/000075045. Dermatology. 2004. PMID: 14730236

6

Significance of cell kinetic parameters in the prognosis of malignant melanoma: a review.

Vereecken P, Laporte M, Heenen M. Vereecken P, et al. J Cutan Pathol. 2007 Feb;34(2):139-45. doi: 10.1111/j.1600-0560.2006.00588.x. J Cutan Pathol. 2007. PMID: 17244025 Review.

7

Recurrent lentigo maligna melanoma: regression associated with local azelaic acid 20%.

Vereecken P, Heenen M. Vereecken P, et al. Int J Clin Pract. 2002 Jan-Feb;56(1):68-9. Int J Clin Pract. 2002. PMID: 11831841

8

Spread of melanoma after lymphatic drainage: relaunching the debate.

Vereecken P, Mathieu A, Laporte M, Petein M, Heenen M. Vereecken P, et al. Int J Clin Pract. 2003 Jun;57(5):444-5. Int J Clin Pract. 2003. PMID: 12846356

9

[Re: innovative therapeutic approaches in melanoma].

Vereecken P, Awada A, Devriendt D, Laporte M, Heenen M, Salès F, Cappello M. Vereecken P, et al. Rev Med Brux. 2004 Dec;25(6):S 542. Rev Med Brux. 2004. PMID: 15688894 French. No abstract available.

10

Decreased immunoreactive maspin expression in intermediate thickness and thick primary melanoma lesions.

Vereecken P, Reynaert S, Lalmand MC, Zouaoui-Boudjeltia K, Heenen M, Van Den Heule B, Petein M. Vereecken P, et al. J Int Med Res. 2006 Jan-Feb;34(1):52-7. doi: 10.1177/147323000603400106. J Int Med Res. 2006. PMID: 16604823 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

107 results

Search Page

Filters